Methylphenidate may diminish antihypertensive effects. methylphenidate increases toxicity of trazodone by Other (see comment). Avoid or Use Alternate Drug. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Manage and view all your plans together even plans in different states. Methylphenidate OROS tablets are converted in an 18:5 ratio with methylphenidate. promazine, methylphenidate. Use Caution/Monitor. Contraindicated (1)phenelzine increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)esketamine intranasal, methylphenidate. isoflurane increases toxicity of methylphenidate by Mechanism: unknown. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of irbesartan by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. albuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvcml0YWxpbi1zci1tZXRoeWxwaGVuaWRhdGUtMzQyOTk5. Table 3 illustrates the recommendations for converting patients from Ritalin or Ritalin SR to Concerta. doxepin, methylphenidate. Applies only to oral form of both agents. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Contraindicated. Modify Therapy/Monitor Closely. Applies only to oral form of both agents. methylphenidate will decrease the level or effect of sotalol by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. only. Use Caution/Monitor. dihydroergotamine, methylphenidate. Contraindicated. Mechanism: unknown. Interaction more likely in certain predisposed pts. Either increases effects of the other by serotonin levels. Use Caution/Monitor. methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism. sufentanil SL, methylphenidate. safinamide increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. desipramine, methylphenidate. Monitor BP. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Monitor Closely (2)trifluoperazine, methylphenidate. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of ramipril by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Risk of acute hypertensive episode. Risk of acute hypertensive episode. Use Caution/Monitor. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Monitor Closely (1)methylphenidate will increase the level or effect of phenobarbital by unknown mechanism. Applies only to oral form of both agents. Use Caution/Monitor. Monitor Closely (1)pramipexole, methylphenidate. Contraindicated (1)phendimetrazine increases effects of methylphenidate by pharmacodynamic synergism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor BP. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. This website also contains material copyrighted by 3rd parties. Monitor Closely (1)clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Monitor Closely (1)cocaine topical increases effects of methylphenidate by pharmacodynamic synergism. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Concerta and Ritalin share the same active ingredient. Risk of acute hypertensive episode. Use Caution/Monitor. Monitor BP. Modify Therapy/Monitor Closely. Risk of acute hypertensive episode. Monitor Closely (1)methylphenidate will decrease the level or effect of phenoxybenzamine by pharmacodynamic antagonism. Monitor for hypertension with concomitant use. Minor/Significance Unknown. Use Caution/Monitor. Monitor BP. Use Caution/Monitor. Interaction specifically associated with Ritalin LA. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Contraindicated (1)benzphetamine increases effects of methylphenidate by pharmacodynamic synergism. Contraindicated. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Monitor Closely (2)perphenazine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)thiothixene increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Applies only to oral form of both agents. Potential for additive CNS stimulation. Use Caution/Monitor. Monitor BP. Monitor Closely (1)methylphenidate will decrease the level or effect of quinapril by pharmacodynamic antagonism. The generic drug name of Concerta is methylphenidate. Contraindicated. 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Risk of acute hypertensive episode. Contraindicated. Use Caution/Monitor. Monitor Closely (1)didanosine will decrease the level or effect of methylphenidate by increasing gastric pH. Indication: attention-deficit/hyperactivity disorder (ADHD). rasagiline increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Use Caution/Monitor. Interaction more likely in certain predisposed pts. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Monitor Closely (1)iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. ropinirole, methylphenidate. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Monitor Closely (1)methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Monitor BP. Use Caution/Monitor. Risk of acute hypertensive episode. Risk of acute hypertensive episode. Modify Therapy/Monitor Closely. Methylphenidate may diminish antihypertensive effects. Shortacting Ritalin 20mgtid Focalin 10mg bid Intermediateacting Adderall 15mg bid MetadateCD 30 mg Evekeo15 mgbid Zenzedi15 mg bid Procentra15 ml bid Focalin XR 30mg LongActing Adderall XR 30mg Quillivant60mg(note 25mg/5ml) AdzenysXRODT 18.8mg Quillichew60 mg AptensioXR 60mg(actuallyequivto ritalin 25.9 twice a day) Other (see comment). epinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Contraindicated. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)hydralazine, methylphenidate. Use Caution/Monitor. Use Caution/Monitor. Selegiline. Either increases effects of the other by pharmacodynamic synergism. This drug is available at a middle level co-pay. Serious - Use Alternative (1)doxapram increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)desipramine, methylphenidate. Avoid or Use Alternate Drug. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. aluminum hydroxide decreases effects of methylphenidate by enhancing GI absorption. restrictions. Use Caution/Monitor. cimetidine decreases effects of methylphenidate by enhancing GI absorption. epinephrine racemic and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Applies only to oral form of both agents. Conversion dosage should not exceed 72 mg daily. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Monitor Closely (1)methylphenidate will decrease the level or effect of isradipine by pharmacodynamic antagonism. Monitor BP. Modify Therapy/Monitor Closely. Modify Therapy/Monitor Closely. Use Caution/Monitor. Contraindicated. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Use Caution/Monitor. Risk of acute hypertensive episode. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Applies only to oral form of both agents. Sympathomimetics can antagonize the activity of some antihypertensive agents. Applies only to oral form of both agents. Monitor Closely (1)methylphenidate will decrease the level or effect of telmisartan by pharmacodynamic antagonism. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Contraindicated. Contraindicated. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Modify Therapy/Monitor Closely. Use Caution/Monitor. Applies only to oral form of both agents. 10mg (Aptensio XR, Ritalin LA, Metadate CD), 20mg (Aptensio XR, Ritalin LA, Metadate CD), 30mg (Aptensio XR, Ritalin LA, Metadate CD), 40mg (Aptensio XR, Ritalin LA, Metadate CD), 60mg (Aptensio XR, Ritalin LA, Metadate CD), If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue drug, Periodically discontinue treatment to assess condition, If improvement not observed after appropriate dosage adjustment over a one-month period, discontinue treatment, Currently on methylphenidate 5 mg BID or TID: Start Concerta or Relexxii at 18 mg qAM, Currently on methylphenidate 10 mg BID or TID: Start Concerta or Relexxii at 36 mg qAM, Currently on methylphenidate 15 mg BID or TID: Start Concerta or Relexxii at 54 mg qAM, Currently on methylphenidate 20 mg BID or TID: Start Concerta or Relexxii at 72 mg qAM, Since renal clearance is not an important route of clearance, renal insufficiency is expected to have little effect on pharmacokinetics of methylphenidate ER tablets, \No experience with use in patients with hepatic insufficiency, Assess for presence of cardiac disease (eg, family history of sudden death or ventricular arrhythmia), Assess risk of abuse before prescribing and monitor for signs of abuse and dependence during therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate need for use, Adhansia XR: 25 mg PO qAM initially; may titrate up in increments of 10-15 mg at intervals of at least 5 days; dosages 70 mg/day associated with increased incidence of certain adverse reactions, Cotempla XR-ODT (oral disintegrating tablets): 17.3 mg PO qAM initially; may titrate upward weekly by 8.6-17.3 mg increments; not to exceed 51.8 mg/day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO BID 30-45 minutes before breakfast and lunch initially; may increase by 5-10 mg/day at weekly intervals; not to exceed 60 mg/day divided BID/TID, Methylin ER: May be given in place of immediate-release products once daily dose is titrated and the titrated 8-hr dosage corresponds to SR or ER tablet size; not to exceed 60 mg/day, Metadate CD, Ritalin LA: Initial, 20 mg PO qAM; may increase by 10 mg (Ritalin LA) or 10-20 mg (Metadate CD) qWeek to not to exceed 60 mg/day, Quillivant XR (6-12 years): 20 mg PO qAM initially; may titrate at weekly intervals by weekly 10- to 20-mg increments; not to exceed 60 mg/day, QuilliChew ER (chewable extended-release tablets): 20 mg PO qAM initially; may be titrated up or down weekly in increments of 10 mg, 15 mg, or 20 mg, not to exceed 60 mg/day, Initial: 0.3 mg/kg/dose PO before breakfast and lunch; may increase by 0.1 mg/kg/dose qWeek, Maintenance: 0.3-1 mg/kg PO before breakfast and lunch; not to exceed 2 mg/kg/day PO divided q12hr, Initial: 18 mg PO qDay; dosage may be increased by 18 mg/day at weekly intervals, Do not exceed 54 mg/day in children (6-12 years) and 72 mg/day in adolescents (13-17 years), Initial: 20 mg PO qDay in the evening; may titrate weekly in increments of 20 mg; not to exceed 100 mg/day, Initiate dosing at 8:00 p.m.; adjust timing of administration between 6:30 pm and 9:30 pm to optimize tolerability and efficacy the next morning and throughout the day, Methylin, Ritalin (immediate-release tablets and oral solution): 5 mg PO q12hr; may increase by 5-10 mg/day weekly; not to exceed 60 mg/day, Methylin ER,: May be given in place of immediate-release products once the daily dose is titrated and the titrated 8-hour dosage corresponds to ER tablet size; not to exceed 60 mg/day, No experience with use in patients with hepatic insufficiency, Assess risk of abuse before prescribing and monitor for signs of abuse and dependence while on therapy, Maintain careful prescription records, educate patients about abuse, and periodically re-evaluate the need for use, Patients <6 years of age experienced higher plasma exposure than patients aged 6 at the same dose and high rates of adverse reactions, most notably weight loss, CNS stimulants, including methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence, Assess the risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, Motor tics or family history or diagnosis of Tourette syndrome, Patients with marked anxiety, tension, and agitation, Contains sucrose; do not administer to patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency, Tablet formulation is nondeformable and does not appreciably change in shape in the GI tract, Do not administer to patients with pre-existing severe gastrointestinal narrowing conditions, including esophageal motility disorders,small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, cystic fibrosis, history of peritonitis, or chronic intestinal pseudo-obstruction, or Meckel diverticulum, Use only in patients who can swallow tablets whole, CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a preexisting psychotic disorder, CNS stimulants may also induce a manic or mixed episode in patients, Before initiating treatment, screen for risk factors for developing a manic episode (eg, history or family history of suicide, bipolar disorder, and depression), CNS stimulants at recommended doses, may cause psychotic or manic symptoms (eg, hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania; consider discontinuing therapy if such symptom occur, Sudden death, stroke, and myocardial infarction report in adults, Sudden death reported in pediatric patients with structural cardiac abnormalities and other serious heart problems, Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, and other serious heart problems, Further evaluate for developing exertional chest pain, unexplained syncope, or arrhythmias during treatment, 45-mg capsules contain FD&C yellow #5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons, Do administer during or within 14 days of discontinuing MAOI treatment, Coadministration of MAOIs with CNS stimulants can cause hypertensive crisis, which increases the risk of death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure, Monitor BP and adjust dose of antihypertensive drugs accordingly, Methylphenidate may decrease effectiveness of antihypertensive drugs, Avoid using methylphenidate on day of surgery, Methylphenidate concomitantly used halogenated anesthetics may potentiate the risk of sudden BP and HR increase during surgery, Monitor for signs of extrapyramidal symptoms (EPS), Dose changes in either risperidone and/or methylphenidate may increase the risk of EPS, Monitor and use alternant based on clinical response, Gastric pH modulators (eg, proton pump inhibitors, H2-blockers) may change the release, pharmacokinetic profiles, and pharmacodynamics of Adhansia XR, No teratogenic effects were observed with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 2x and 9x the maximum recommended human dose (MRHD) of 100 mg/day given to adolescents on a mg/m2 basis, respectively, However, spina bifida was observed in rabbits at a dose 31x the MRHD given to adolescents, Decrease in pup body weight was observed in a pre- and postnatal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 3.5x the MRHD given to adolescents, CNS stimulant medications can cause vasoconstriction and thereby decrease placental perfusion, No fetal and/or neonatal adverse reactions reported with use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers, Monitors pregnancy outcomes in females exposed to ADHD medications, Encourage providers to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388, ER tablets: 19.3-19.7 ng/mL(72-mg dose); 3.7 ng/mL (18 mg-dose), Aptensio XR: 23.47 ng/mL (capsule); 21.78 ng/mL (sprinkle), ER tablets: 5.5 hr (72-mg dose); 6.8 hr (18-mg dose), Adhansia XR: 1.5 hr (1st median range time); 12 hr (2nd median range time), ER tablets: 200.9-206.1 nghr/mL (72-mg dose); 41.8 nghr/mL (18-mg dose), Aptensio XR: 258.1-262.7 nghr/mL (capsule): 258-262.9 nghr/mL (sprinkle), Aptensio XR: 5.09 hr (capsule); 5.43 hr (sprinkle), Urine: 90% (80% main urinary metabolite PPAA), Take orally in the morning with or without food, Swallow tablet whole with liquid; do not chew, divide, or crush, If switching from other methylphenidate products, discontinue that treatment, and titrate with QuilliChew ER using the titration schedule (see Pediatric Dosing), Ritalin: Swallow whole, do not crush or chew, Ritalin LA capsule: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately, Take all formulations 30-45 minutes before meals, Metadate CD: Swallow whole, do not crush or chew; may open capsule and sprinkle contents on applesauce and consumed immediately; administer once daily in AM, Shake bottle vigorously for at least 10 seconds before measuring dose, Use dry hands when opening the blister pack, Do not remove the tablet from the blister pack until just before dosing, Remove tablet by peeling back foil on blister pack; do not push the tablet through the foil, Administer immediately after opening by placing the tablet on patients tongue and letting it dissolve; do not chew or crush, Disintegrate in saliva so that it can be swallowed; no liquid is needed to take the tablet, Following determination of optimal administration time, advise patients to maintain a consistent dosing time, Advise patients to take the dose consistently either with or without food, May take capsule whole, or may be opened and the entire contents sprinkled onto applesauce; if patient is using the sprinkled administration method, the sprinkled applesauce should be consumed immediately and not stored and should be taken in its entirety without chewing; the dose of a single capsule should not be divided and should be taken at the same time, Periodically reevaluate long term use and adjust dosage as needed, Take dose as soon possible that same evening; if patient remembers the missed dose the following morning, skip missed dose and wait until next scheduled evening administration, If switching from other methylphenidate products, discontinue that treatment, and titrate with Jornay PM using the titration schedule described above, Swallow whole or open capsule and sprinkle entire contents onto 1 tablespoon of applesauce or yogurt; consume entire mixture immediately or within 10 min, Take the entire contents of capsule sprinkled on chosen food in its entirety, without chewing, Discard mixture if not consumed within 10 min; do not store, Do not divide capsules nor take <1 capsule/day, Do not administer additional medication to make up for missed, Switching from other methylphenidate products: Discontinue current treatment and titrate with Adhansia XR using titration schedule.

Madison County, Il Court Records Search, Contenance Club San Diego, Articles C